Strict control of comorbidities in patients with chronic obstructive pulmonary disease decreases exacerbations, morbimortality, and avoids readmissions. An increasing number of women have the disease, ...
Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality globally. Effective management ...
A quasi-experimental study found anticipatory nursing in chronic obstructive pulmonary disease lowered anxiety and depression ...
Chronic obstructive pulmonary disease (COPD) remains a substantial contributor to morbidity and mortality in the United States with an estimated 3.8% age-adjusted prevalence and 141,733 COPD deaths ...
Chronic obstructive pulmonary disease (COPD) is a progressive respiratory disorder characterised by persistent airflow limitation and chronic inflammation. Beyond its primary pulmonary manifestations, ...
AirNexis Therapeutics is a clinical-stage biotech company developing novel therapeutic drugs for the treatment of COPD patients. AN01 is a dual PDE3/4 inhibitor that exerts synergistic effects through ...
Background Exacerbations are major causes of morbidity in individuals with chronic respiratory diseases such as chronic ...
We currently know that COPD, and specifically emphysema, is not just a lung disease found alongside lung cancer; it increases ...
In 2021, an estimated 14 million adults in the United States reported a diagnosis of chronic obstructive pulmonary disease (COPD), chronic bronchitis, or emphysema. If you’re not sure what the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback